Daily Sepsis Research Analysis
Three impactful studies advance sepsis science and care: a mechanistic paper uncovers a PGC-1α–migrasome pathway driving sepsis-associated pulmonary fibrosis, a multicenter double-blind RCT suggests sivelestat may improve early oxygenation in sepsis-induced ARDS, and a large U.S. cohort reveals delayed and sparse AST reporting for next-generation agents in Gram-negative bloodstream infections. Together, they highlight targets for antifibrotic strategies, potential adjunctive therapy in ARDS, and
Summary
Three impactful studies advance sepsis science and care: a mechanistic paper uncovers a PGC-1α–migrasome pathway driving sepsis-associated pulmonary fibrosis, a multicenter double-blind RCT suggests sivelestat may improve early oxygenation in sepsis-induced ARDS, and a large U.S. cohort reveals delayed and sparse AST reporting for next-generation agents in Gram-negative bloodstream infections. Together, they highlight targets for antifibrotic strategies, potential adjunctive therapy in ARDS, and urgent microbiology workflow improvements.
Research Themes
- Sepsis-induced organ injury mechanisms and fibrosis
- Adjunctive therapeutics in sepsis-induced ARDS
- Diagnostic microbiology performance and stewardship in bloodstream infections
Selected Articles
1. PGC-1α mediates migrasome secretion accelerating macrophage-myofibroblast transition and contributing to sepsis-associated pulmonary fibrosis.
Using LPS-induced models, the authors show that PGC-1α suppression in lung fibroblasts causes mitochondrial dysfunction and release of mtDNA-laden migrasomes, which trigger macrophage–myofibroblast transition and drive sepsis-associated pulmonary fibrosis. Restoring PGC-1α attenuated migrasome release, inhibited MMT, and alleviated fibrosis, revealing a targetable fibroblast–immune cell crosstalk.
Impact: This work identifies a previously unrecognized migrasome-based mechanism linking fibroblast mitochondrial stress to macrophage transdifferentiation in sepsis-related fibrosis, opening a tractable therapeutic axis (PGC-1α/migrasomes).
Clinical Implications: Although preclinical, the data suggest that enhancing PGC-1α or interrupting migrasome signaling could prevent or mitigate post-sepsis pulmonary fibrosis, potentially improving long-term outcomes after sepsis/ARDS.
Key Findings
- LPS suppressed PGC-1α in lung fibroblasts, inducing mitochondrial dysfunction and cytosolic mtDNA accumulation.
- Fibroblast stress promoted secretion of mtDNA-containing migrasomes that initiated macrophage–myofibroblast transition (MMT).
- Activation of PGC-1α reduced migrasome release, inhibited MMT, and alleviated sepsis-associated pulmonary fibrosis in vivo.
Methodological Strengths
- Complementary in vivo (LPS-induced SAPF) and in vitro co-culture systems delineating causality.
- Mechanistic links established from mitochondrial dysfunction to vesicle-mediated intercellular signaling and phenotypic transition.
Limitations
- Preclinical models; human validation in sepsis survivors with fibrosis is lacking.
- LPS-induced injury may not recapitulate all aspects of clinical SAPF heterogeneity.
Future Directions: Validate PGC-1α/migrasome signatures in human biospecimens post-sepsis, and test pharmacologic PGC-1α activators or migrasome pathway inhibitors in translational models.
Sepsis-associated pulmonary fibrosis (SAPF) is a critical pathological stage in the progression of sepsis-induced acute respiratory distress syndrome. While the aggregation and activation of lung fibroblasts are central to the initiation of pulmonary fibrosis, the macrophage-myofibroblast transition (MMT) has recently been identified as a novel source of fibroblasts in this context. However, the mechanisms driving MMT remain inadequately understood. Given the emerging role of migrasomes (novel extracellular vesicles mediating intercellular communication), we investigated their involvement in pulmonary fibrosis. Here we utilized a lipopolysaccharide-induced SAPF mouse model and an in vitro co-culture system of fibroblasts and macrophages to observe the MMT process during SAPF. We found that lipopolysaccharide exposure suppresses PGC-1α expression in lung fibroblasts, resulting in mitochondrial dysfunction and the accumulation of cytosolic mitochondrial DNA (mtDNA). This dysfunction promotes the secretion of mtDNA-containing migrasomes, which, in turn, initiate the MMT process and contribute to fibrosis progression. Notably, the activation of PGC-1α mitigates mitochondrial dysfunction, reduces mtDNA-migrasome release, inhibits MMT and alleviates SAPF. In conclusion, our study identifies the suppression of PGC-1α in lung fibroblasts and the subsequent release of mtDNA migrasomes as a novel mechanism driving MMT in SAPF. These findings suggest that targeting the crosstalk between fibroblasts and immune cells mediated by migrasomes could represent a promising therapeutic strategy for SAPF.
2. Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) on Oxygenation in Patients with Sepsis-Induced Acute Respiratory Distress Syndrome.
In a multicenter, double-blind RCT (n=70) stopped early, sivelestat improved early oxygenation in sepsis-induced ARDS, with a signal toward lower 28-day mortality. Patients were randomized within 48 hours and received continuous infusion for 5–14 days.
Impact: A placebo-controlled RCT targeting neutrophil elastase in sepsis-induced ARDS provides randomized evidence for a long-debated therapy and may influence future trials and practice if validated.
Clinical Implications: Sivelestat may be considered for study in larger confirmatory trials for sepsis-induced ARDS, and its early use could target neutrophil-driven lung injury. Current data are insufficient for routine adoption.
Key Findings
- Multicenter, double-blind, randomized, placebo-controlled trial enrolled 70 patients within 48 hours of sepsis-induced ARDS onset.
- Sivelestat improved oxygenation within the first five days compared with placebo.
- Interim analysis suggested a between-group mortality difference; the trial was stopped early with a signal toward lower 28-day mortality in the sivelestat arm.
Methodological Strengths
- Multicenter double-blind randomized placebo-controlled design with early enrollment.
- Protocolized continuous infusion and predefined primary outcome on oxygenation.
Limitations
- Stopped early with small sample size, underpowering definitive mortality conclusions.
- Abstract truncation limits detailed endpoint reporting; full data needed for appraisal.
Future Directions: Conduct adequately powered, CONSORT-compliant RCTs with mortality and ventilator-free days as primary endpoints, and biomarker-guided enrichment to identify responders.
OBJECTIVE: Neutrophil elastase (NE) plays an important role in the development of acute respiratory distress syndrome (ARDS). Sivelestat sodium, as a selective NE inhibitor, may improve the outcomes of patients with sepsis-induced ARDS in previous studies, but there is a lack of solid evidence. This trial aimed to evaluate the effect of sivelestat sodium on oxygenation in patients with sepsis-induced ARDS. METHODS: We conducted a multicenter, double-blind, randomized, placebo-controlled trial enrolling patients diagnosed with sepsis-induced ARDS admitted within 48 hours of the advent of symptoms. Patients were randomized in a 1:1 fashion to sivelestat or placebo. Trial drugs were administered as a 24-hour continuous intravenous infusion, for a minimum duration of 5 days and a maximum duration of 14 days. The primary outcome was the proportion of PaO RESULTS: The study was stopped midway due to a potential between-group difference in mortality observed during the interim analysis. Overall, a total of 70 patients were randomized, of whom 34 were assigned to receive sivelestat sodium and 36 placebo. On day 5, 19/34 (55.9%) patients in the sivelestat group had PaO CONCLUSION: In patients with sepsis-induced ARDS, sivelestat sodium could improve oxygenation within the first five days and may be associated with decreased 28-day mortality.
3. Microbiology Laboratory Testing Practices of Gram-Negative Bloodstream Infections With Difficult-to-Treat Resistant Phenotypes in US Hospitals.
In 110,322 Gram-negative BSI episodes across U.S. hospitals, AST reporting took on average 73.5 hours and was even slower for DTR and carbapenem-nonsusceptible phenotypes (~92 hours). AST for next-generation agents was infrequently reported (2.5% overall; 30.5% in DTR cases), highlighting diagnostic delays that likely hinder optimal therapy.
Impact: This national analysis quantifies AST delays and under-reporting for next-generation agents in resistant GN-BSI, providing actionable targets for lab workflow optimization and stewardship policies.
Clinical Implications: Hospitals should prioritize rapid AST workflows and routine panels for next-generation agents in high-risk phenotypes to shorten time-to-targeted therapy, potentially improving outcomes in resistant GN-BSI.
Key Findings
- AST time-to-result averaged 73.5 ± 26.7 hours; DTR and carbapenem-nonsusceptible phenotypes had longer times (~92 hours).
- Only 2.5% of episodes had AST reported for ≥1 next-generation agent, increasing from 0.2% (2017) to 7.7% (2023).
- Among DTR isolates, just 30.5% had AST for at least one next-generation antimicrobial.
Methodological Strengths
- Very large, geographically diverse cohort over multiple years.
- Phenotype-stratified analysis including newer antimicrobials relevant to current practice.
Limitations
- Administrative database may lack granular clinical outcomes and confounders.
- Observational design cannot establish causal links between AST timing and patient outcomes.
Future Directions: Implement and study rapid AST/next-generation panels with time-to-appropriate therapy and mortality as endpoints; evaluate cost-effectiveness and stewardship-driven algorithms.
BACKGROUND: Rapid administration of effective antimicrobial therapy is crucial for managing bloodstream infections (BSIs), especially those caused by pathogens with difficult-to-treat resistance (DTR; ie, resistance to all first-line antimicrobials). The purpose of this study is to describe the epidemiology and time course of microbiological testing in US laboratories for gram-negative BSIs (GN-BSIs). METHODS: A retrospective observational cohort study of adults with GN-BSI between 1 January 2017 and 30 June 2023 was conducted using a large, geographically diverse, hospital-based administrative US database. Antimicrobial susceptibility testing (AST) reporting and time to results of traditional and next-generation antimicrobials (ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, meropenem-vaborbactam, imipenem-relebactam) were evaluated according to the isolates' resistance phenotype. RESULTS: A total of 110 322 GN-BSI episodes were included, of which 0.6% exhibited a DTR phenotype. Among all episodes, the average time to results for AST was 73.5 ± 26.7 hours from blood culture collection. The average time to AST results was longer for DTR (92.2 ± 27.8 hours) and carbapenem not-susceptible phenotypes (90.1 ± 28.0 hours) than for nonresistant phenotypes (72.9 ± 26.7 hours). Overall, 2.5% of GN-BSI episodes had AST reported for at least 1 next-generation antimicrobial, increasing from 0.2% in 2017 to 7.7% in 2023. Among patients with isolates showing DTR phenotypes, 30.5% had AST reported for at least 1 next-generation antimicrobial. CONCLUSIONS: Time to AST results for next-generation antimicrobials and antibiotic-resistant organisms is prolonged in US laboratories for blood cultures with gram-negative organisms. Testing frequency and timing of AST reporting for next-generation antimicrobials likely contribute to their clinical utilization.